Int. J. Curr. Res. Med. Sci. (2024). 10(10): 32-41

International Journal of Current Research in Medical Sciences

ISSN: 2454-5716

(A Peer Reviewed, Indexed and Open Access Journal)

www.ijcrims.com

Review Article

Volume 10, Issue 10 -2024

DOI: http://dx.doi.org/10.22192/ijcrms.2024.10.10.005

Mentzer Index and Pregnancy: Utility in Differentiating Iron Deficiency Anemia and Thalassemia

*[1]Emmanuel Ifeanyi Obeagu and [2]Getrude Uzoma Obeagu

[1]Department of Biomedical and Laboratory Science, Africa University, Zimbabwe

[2]School of Nursing Science, Kampala International University, Uganda.

*Corresponding author: *emmanuelobeagu@yahoo.com*

Abstract

The Mentzer Index is a widely recognized tool for differentiating types of microcytic anemia, particularly in pregnant populations where anemia is prevalent. This review article examines the utility of the Mentzer Index in identifying iron deficiency anemia (IDA) and thalassemia trait among pregnant women. Given the physiological changes that occur during pregnancy, the accurate diagnosis of anemia is critical to prevent adverse maternal and fetal health outcomes. The Mentzer Index, calculated as the ratio of mean corpuscular volume (MCV) to hemoglobin concentration, provides a straightforward and cost-effective method for distinguishing between these two types of anemia. The application of the Mentzer Index is particularly beneficial in clinical settings where rapid assessment is necessary. An index value of less than 13 generally suggests thalassemia, while values greater than 13 indicate IDA. This ability to differentiate anemia types allows healthcare providers to tailor treatment strategies, ensuring appropriate management such as iron supplementation for IDA or genetic counseling for thalassemia trait. However, it is essential to recognize the limitations of the Mentzer Index, including its dependency on accurate laboratory measurements and the potential for overlapping clinical features.

Keywords: Mentzer Index, pregnancy, iron deficiency anemia, thalassemia, microcytic anemia, diagnosis, prenatal care, maternal health.

Introduction

Anemia during pregnancy is a widespread health concern affecting millions of women globally, with significant implications for maternal and fetal well-being. Defined as a reduction in hemoglobin concentration, anemia can lead to adverse outcomes such as fatigue, reduced physical capacity, and increased susceptibility to infections. In severe cases, it can contribute to preterm delivery, low birth weight, and even maternal mortality. Among pregnant women, the

most prevalent types of anemia are iron deficiency anemia (IDA) and thalassemia trait, both of which require distinct management strategies. Accurate diagnosis is essential to ensure effective treatment and mitigate potential risks to both the mother and the developing fetus.[1-2] Iron deficiency anemia is primarily caused by insufficient iron stores, often due to increased demands during pregnancy, dietary deficiencies, or chronic blood loss. IDA is characterized by microcytic hypochromic red blood cells, low serum ferritin, and elevated total iron-binding capacity. Symptoms may include fatigue, weakness, and pallor, which can significantly impact the quality of life and overall health of pregnant women. On the other hand, thalassemia is a hereditary blood disorder that leads to decreased hemoglobin production. Women with thalassemia trait often present with mild anemia and may be asymptomatic. However, the presence of thalassemia can pose genetic risks for offspring, making it critical to distinguish between IDA and thalassemia during pregnancy.[3-5] The differentiation between IDA and thalassemia is particularly challenging due to overlapping clinical features and the physiological changes that occur during pregnancy. Traditional laboratory tests, such as complete blood count (CBC) and iron studies, are often utilized; however, they may not provide conclusive results in every case. As a result, there is a growing interest in diagnostic tools that offer a more straightforward approach to identifying the specific type of anemia present. One such tool is the Mentzer Index, which has been gaining traction in clinical settings for its simplicity and effectiveness.[6]

An index value of less than 13 typically indicates thalassemia trait, while a value greater than 13 suggests iron deficiency anemia. This index is particularly advantageous in the context of pregnancy, as it leverages readily available laboratory parameters to provide a rapid preliminary assessment of anemia type. Given the time-sensitive nature of prenatal care, the Mentzer Index offers a practical solution for healthcare providers seeking to optimize patient management. Despite its utility, the Mentzer Index is not without limitations. Its accuracy can be influenced by factors such as hydration status, laboratory variability, and coexisting conditions that may affect red blood cell morphology. Moreover, the index may not account for all types of microcytic anemia, particularly when both IDA and thalassemia coexist. Therefore, it is essential for healthcare providers to be aware of these limitations and consider using complementary diagnostic indices alongside the Mentzer Index to enhance overall diagnostic accuracy.[7] The integration of the Mentzer Index into routine prenatal care holds significant promise for improving anemia diagnosis and management. As awareness of the critical importance of addressing anemia during pregnancy grows, the ability to differentiate between IDA and thalassemia in a timely and cost-effective manner becomes paramount. By enhancing diagnostic accuracy, healthcare providers can tailor treatment plans to meet the specific needs of pregnant women, thereby improving maternal and fetal health outcomes.[8]

Overview of the Mentzer Index

The Mentzer Index is a widely used hematological tool designed to differentiate between types of microcytic anemia, particularly iron deficiency anemia (IDA) and thalassemia trait. Introduced by Dr. Michael Mentzer in the 1970s, this index provides a simple yet effective formula that allows healthcare providers to classify anemias based on readily available laboratory parameters. Where MCV refers to the mean corpuscular volume, which measures the average size of red blood cells, and hemoglobin indicates the concentration of hemoglobin in the blood. The resulting value of the Mentzer Index can be interpreted to help differentiate between IDA and thalassemia, with a value less than 13 suggesting thalassemia and a value greater than 13 indicating IDA.[9] The simplicity of the Mentzer Index makes it particularly appealing in clinical practice. Unlike more complex diagnostic methods that may require specialized equipment or lengthy procedures, the Mentzer Index relies solely on two commonly measured parameters available in standard complete blood count (CBC) tests. This accessibility allows for rapid screening and assessment, making it an invaluable tool in

settings such as obstetric care, where timely diagnosis is critical for maternal and fetal health.[10] In addition to its ease of use, the Mentzer Index has been shown to correlate well with other diagnostic criteria for differentiating between IDA and thalassemia. Research studies have indicated that the index can accurately classify most patients with microcytic anemia, aiding clinicians in deciding on appropriate treatment strategies. For instance, individuals identified as having IDA can benefit from iron supplementation and dietary modifications, while those with thalassemia may require genetic counseling and monitoring for potential complications.[11] Despite its utility, the Mentzer Index is not infallible. Several factors can influence its accuracy, including hydration status, variations in laboratory techniques, and the presence of other underlying conditions that may affect red blood cell morphology. For example, conditions such as anemia of chronic disease or sideroblastic anemia can complicate the interpretation of the Mentzer Index, leading to potential misclassification of the anemia type. As such, it is essential for healthcare providers to be aware of these limitations and to use the Mentzer Index as part of a broader diagnostic approach.

Types of Anemia in Pregnancy

Anemia is a common hematological disorder in pregnant women, characterized by a decrease in the number of red blood cells or hemoglobin concentration, leading to insufficient oxygen transport to tissues. The prevalence of anemia during pregnancy can be attributed to various factors, including increased physiological demands, dietary deficiencies, and underlying medical conditions. The major types of anemia encountered during pregnancy include iron deficiency anemia (IDA), folate deficiency anemia, vitamin B12 deficiency anemia, and thalassemia.[12]

1. Iron Deficiency Anemia (IDA)

Iron deficiency anemia is the most prevalent form of anemia in pregnancy, affecting a significant percentage of pregnant women worldwide. During pregnancy, the body requires additional iron to support the increased blood volume and to meet the iron needs of the developing fetus and placenta. Inadequate dietary intake, poor absorption, or increased iron demand can lead to depleted iron stores, resulting in IDA. Clinically, IDA is characterized by microcytic and hypochromic red blood cells, low serum ferritin levels, and elevated total iron-binding capacity. Symptoms may include fatigue, pallor, and weakness. Early detection and treatment with iron supplementation and dietary modifications are essential to prevent complications such as preterm delivery, low birth weight, and maternal fatigue.[13]

2. Folate Deficiency Anemia

Folate deficiency anemia occurs when there is insufficient folate (vitamin B9) to support the production of red blood cells. Folate is essential for DNA synthesis and cell division, making it particularly important during periods of rapid growth, such as pregnancy. Increased requirements for folate arise during pregnancy to support fetal development, particularly during the first trimester when the neural tube is forming. A deficiency can lead to megaloblastic anemia, which is characterized by the presence of large, immature red blood cells (macrocytes) in the blood. Symptoms may include fatigue, irritability, and shortness of breath. Pregnant women are advised to take prenatal vitamins that contain folic acid to prevent deficiency and its associated complications, such as neural tube defects in the fetus.[14]

3. Vitamin B12 Deficiency Anemia

Vitamin B12 deficiency anemia is another type of megaloblastic anemia that can occur during pregnancy. Vitamin B12 is vital for proper red blood cell formation and neurological function. Pregnant women who are vegetarian or vegan, or those with malabsorption syndromes, may be at higher risk of vitamin B12 deficiency. Symptoms may include fatigue, weakness, neurological disturbances, and megaloblastic changes in the bone marrow. Similar to folate deficiency, vitamin B12 deficiency can lead to adverse pregnancy outcomes, including developmental delays and complications during delivery. Pregnant women should be screened for vitamin

B12 levels, and supplementation should be initiated if a deficiency is identified.[15]

4. Thalassemia

Thalassemia is a hereditary blood disorder characterized by reduced or absent production of hemoglobin chains, leading to microcytic anemia. The two main types of thalassemia are alpha and beta thalassemia, each caused by genetic mutations affecting different globin chains. Pregnant women with thalassemia trait often present with mild anemia and may be asymptomatic. However, the condition can complicate pregnancy if not recognized, as it may lead to increased risk for maternal complications and fetal growth restrictions. Genetic counseling and regular monitoring are essential for managing thalassemia during pregnancy. Differentiating thalassemia from IDA is crucial, as treatment strategies differ significantly.[16]

5. Anemia of Chronic Disease

Anemia of chronic disease (ACD) is often seen in pregnant women with chronic inflammatory conditions, infections, or malignancies. ACD is characterized by normocytic or microcytic anemia and results from the body's response to inflammation, which affects iron metabolism and erythropoiesis. Unlike IDA, ACD typically does not respond well to iron supplementation.

Mentzer Index in Differentiating Anemia Types

The Mentzer Index is a valuable diagnostic tool used to differentiate between types of microcytic anemia, primarily iron deficiency anemia (IDA) and thalassemia trait. This index is particularly useful in clinical settings due to its simplicity and the reliance on easily obtainable laboratory parameters.

1. Interpretation of the Mentzer Index

A Mentzer Index value of **less than 13** typically suggests thalassemia trait, while a value of **greater than 13** indicates iron deficiency anemia. This clear demarcation aids clinicians in making rapid decisions regarding further testing and treatment. For instance, a patient presenting with microcytic anemia and a Mentzer Index of 10 is more likely to have thalassemia trait, while one with an index of 15 would be considered to have IDA.

2. Clinical Relevance in Pregnancy

During pregnancy, distinguishing between IDA and thalassemia is particularly important due to the differing management approaches for these conditions. Iron deficiency anemia is often treated with iron supplementation and dietary modifications to restore iron levels and improve hemoglobin concentration. In contrast, thalassemia requires careful monitoring and may necessitate genetic counseling to understand the implications for the fetus. The Mentzer Index offers a rapid screening tool that can facilitate timely interventions, especially in obstetric settings where rapid diagnostic processes are essential for maternal and fetal health.[17] Additionally, the physiological changes of pregnancy can complicate the diagnosis of anemia. For example, the increase in plasma volume during pregnancy can dilute hemoglobin concentrations, potentially masking underlying anemia. The Mentzer Index provides an additional layer of clarity in this context, helping clinicians discern whether the anemia is primarily due to iron deficiency or a hereditary condition like thalassemia.[18]

3. Limitations of the Mentzer Index

While the Mentzer Index is a useful diagnostic tool, it is not without its limitations. Factors such as hydration status, laboratory variability, and the presence of other hematological conditions can affect the accuracy of the index. For instance, patients with anemia of chronic disease may present with similar laboratory parameters to those with IDA or thalassemia, potentially leading to misinterpretation of the Mentzer Index results. Moreover, the Mentzer Index does not provide information on other types of anemia, such as folate deficiency or anemia of chronic disease, which may also present with microcytic red blood

cells. Therefore, it should be used as part of a comprehensive diagnostic approach that includes a thorough clinical history, physical examination, and additional laboratory tests when necessary.

Benefits of Using the Mentzer Index in Pregnancy

The Mentzer Index is a valuable tool in the assessment and management of anemia during pregnancy, particularly in differentiating between iron deficiency anemia (IDA) and thalassemia trait. Its utility is grounded in several benefits that contribute to improved maternal and fetal health outcomes. Below are some key advantages of employing the Mentzer Index in clinical practice during pregnancy.[19]

1. Simplicity and Ease of Use

One of the primary benefits of the Mentzer Index is its simplicity. The calculation involves only two readily available laboratory parameters: mean corpuscular volume (MCV) and hemoglobin concentration. This straightforward formula allows healthcare providers to quickly assess and interpret anemia types without the need for complex testing or specialized equipment. In busy obstetric settings, where timely decision-making is essential, the Mentzer Index enables clinicians to make rapid evaluations, facilitating quicker diagnosis and intervention.

2. Rapid Differentiation of Anemia Types

The ability to differentiate between IDA and thalassemia trait using the Mentzer Index is particularly important in pregnancy, where treatment approaches differ significantly. Iron deficiency anemia is commonly managed with iron supplementation and dietary changes, while thalassemia requires careful monitoring and possibly genetic counseling. By providing a clear categorization based on the calculated index, the Mentzer Index aids clinicians in implementing appropriate management strategies more efficiently. This rapid differentiation is crucial in ensuring that pregnant women receive the correct treatment in a timely manner, thus reducing the risk of complications associated with misdiagnosed anemia.

3. Enhancing Clinical Decision-Making

Using the Mentzer Index contributes to informed clinical decision-making. The ability to quickly classify anemia types allows for the prioritization of further testing and intervention. For example, if a pregnant patient presents with microcytic anemia and a low Mentzer Index, clinicians may decide to pursue genetic testing for thalassemia or adjust management plans accordingly. Additionally, understanding the specific type of anemia can guide counseling and education for patients regarding their condition and treatment options, fostering a collaborative approach to care.

4. Cost-Effectiveness

The Mentzer Index enhances cost-effectiveness in anemia management, particularly in resource-limited settings. By relying on basic laboratory parameters that are typically included in routine complete blood count (CBC) tests, the index minimizes the need for more expensive and specialized testing. This is particularly advantageous in settings with limited access to advanced diagnostic facilities. Early identification and appropriate management of anemia can also prevent complications, potentially reducing healthcare costs associated with treating adverse pregnancy outcomes linked to untreated anemia.

5. Improving Maternal and Fetal Outcomes

Early and accurate diagnosis of the type of anemia using the Mentzer Index can significantly improve maternal and fetal health outcomes. Addressing iron deficiency anemia promptly can prevent complications such as preterm labor, low birth weight, and maternal fatigue. Similarly, recognizing thalassemia enables proper monitoring and support, reducing the risk of complications during pregnancy and delivery. By enhancing the accuracy of anemia diagnosis, the Mentzer Index ultimately contributes to safer pregnancies and better health for both mothers and their infants.

6. Facilitating Research and Education

The Mentzer Index serves as a valuable educational tool for healthcare providers and trainees in obstetrics and gynecology. Its use in clinical practice provides a tangible example of how laboratory data can inform diagnostic processes. Furthermore, ongoing research on the efficacy and applications of the Mentzer Index in various populations and settings can contribute to the broader understanding of anemia management during pregnancy. By promoting the use of the Mentzer Index, healthcare professionals can enhance their skills in diagnosing and treating anemia, ultimately benefiting patient care.

Limitations and Challenges

While the Mentzer Index is a useful tool for differentiating between types of microcytic anemia, particularly iron deficiency anemia (IDA) and thalassemia trait, it is not without its limitations and challenges. Understanding these drawbacks is essential for clinicians to ensure accurate diagnosis and effective management of anemia during pregnancy.

1. Variable Laboratory Parameters

The Mentzer Index relies on two key laboratory parameters: mean corpuscular volume (MCV) and hemoglobin concentration. Variability in these measurements can arise from multiple factors, including differences in laboratory techniques, equipment calibration, and sample handling. For example, dehydration can lead to hemoconcentration, resulting in falsely elevated hemoglobin levels and potentially misleading Mentzer Index calculations. Such variability may complicate the interpretation of results, especially in a pregnant population where physiological changes can affect blood parameters.

2. Limited Scope of Application

The Mentzer Index is primarily designed to differentiate between IDA and thalassemia trait, focusing on microcytic anemia. However, it does not account for other potential causes of anemia that may also present with similar laboratory findings, such as anemia of chronic disease (ACD) or megaloblastic anemia due to vitamin B12 or folate deficiency. Consequently, clinicians must remain cautious when relying solely on the Mentzer Index for diagnosis, as additional testing and a comprehensive clinical evaluation are necessary to rule out other anemia types.

3. Influence of Pregnancy-Related Changes

Pregnancy introduces a range of physiological changes that can complicate the assessment of anemia. For example, increased plasma volume leads to hemodilution, which may lower hemoglobin concentrations and skew the Mentzer Index results. Additionally, the normal changes in MCV during pregnancy can vary among individuals, making it challenging to establish a consistent reference range for interpreting the index. These factors necessitate careful consideration of the context in which the Mentzer Index is applied during pregnancy.

4. Potential for Misinterpretation

Due to its relative simplicity, there is a risk of over-reliance on the Mentzer Index without considering other clinical factors and laboratory results. For instance, a healthcare provider may interpret a high Mentzer Index as indicative of IDA without thoroughly evaluating the patient's clinical history, dietary intake, or possible underlying conditions. Such misinterpretation can lead to inappropriate management decisions, including unnecessary iron supplementation or failure to address more complex anemia etiologies.

5. Need for Complementary Diagnostic Tools

To enhance the accuracy of anemia diagnosis during pregnancy, the Mentzer Index should be used in conjunction with other diagnostic tools and assessments. Additional tests such as serum ferritin levels, reticulocyte counts, and peripheral blood smears can provide valuable information about iron stores, red blood cell production, and morphological characteristics of the cells. Relying solely on the Mentzer Index may overlook critical data necessary for comprehensive anemia

evaluation, underscoring the importance of a multifaceted diagnostic approach.

6. Lack of Standardization

There is currently no universal standardization of the Mentzer Index across different laboratories and clinical settings. Variations in normal ranges, cut-off values, and calculation methods can lead to discrepancies in interpretation and clinical application. This lack of standardization can hinder the widespread adoption of the Mentzer Index as a diagnostic tool and complicate comparisons between studies and clinical practices.

Alternative Diagnostic Indices

While the Mentzer Index is a valuable tool for differentiating between iron deficiency anemia (IDA) and thalassemia trait, several alternative diagnostic indices and methods can aid in the evaluation of anemia, particularly in pregnant women. These alternatives may offer additional insights and can be used in conjunction with the Mentzer Index to enhance diagnostic accuracy. Below are some notable alternative indices and diagnostic tools.

1. Soluble Transferrin Receptor (sTfR) Level

The soluble transferrin receptor (sTfR) is a protein that reflects the body's iron status and helps distinguish between IDA and anemia of chronic disease (ACD). Elevated levels of sTfR are indicative of iron deficiency, as they signify increased erythropoiesis due to low iron availability. In contrast, normal or low sTfR levels in the presence of low hemoglobin can indicate ACD. This marker is particularly useful in pregnant women, where inflammatory states can complicate anemia diagnosis. Measuring sTfR levels can provide valuable information about iron stores and assist in guiding appropriate treatment.

2. Ferritin Levels

Serum ferritin is a key indicator of iron stores in the body and is widely used in the diagnosis of IDA. Low ferritin levels typically suggest depleted iron stores, making it a critical parameter for anemia evaluation in pregnancy. However, ferritin is an acute phase reactant, meaning its levels can be influenced by inflammatory processes. In cases of infection or inflammation, ferritin levels may be elevated even in the presence of iron deficiency. Therefore, interpreting ferritin results in the context of overall clinical findings and additional tests is essential.

3. Reticulocyte Count

The reticulocyte count measures the number of young red blood cells (reticulocytes) in the bloodstream and provides insights into bone marrow activity and erythropoietic response. In IDA, reticulocyte counts are usually low due to insufficient iron for hemoglobin synthesis. Conversely, in cases of hemolysis or acute blood loss, reticulocyte counts may be elevated as the bone marrow responds to increased demand for red blood cells. In pregnant women, assessing reticulocyte levels can help determine the cause of anemia and guide further investigations.

4. Red Cell Distribution Width (RDW)

Red cell distribution width (RDW) is a parameter that measures the variation in the size of red blood cells. Increased RDW can indicate the presence of multiple underlying causes of anemia or recent changes in erythropoiesis. In the context of IDA, RDW is often elevated due to the presence of smaller red blood cells alongside larger ones, which may be more typical of thalassemia. Combining RDW with other indices, including the Mentzer Index, can enhance the differentiation of anemia types and provide a more comprehensive picture of the patient’s hematological status.

5. Mean Corpuscular Hemoglobin (MCH) and Mean Corpuscular Hemoglobin Concentration (MCHC)

Mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) are additional red blood cell indices that can

provide valuable information in the diagnosis of anemia. MCH indicates the average amount of hemoglobin per red blood cell, while MCHC reflects the average concentration of hemoglobin in a given volume of packed red blood cells. In IDA, MCH and MCHC are typically low, whereas in thalassemia, MCH may also be low, but MCHC can vary. These indices can further assist in characterizing the type of anemia present in pregnant women.

6. Hematological and Biochemical Profiles

A comprehensive evaluation of anemia should include a detailed hematological and biochemical profile, encompassing parameters such as complete blood count (CBC), vitamin B12, and folate levels. These assessments help identify potential deficiencies or disorders contributing to anemia. In pregnancy, assessing for deficiencies in vitamin B12 or folate is particularly important, as these can lead to megaloblastic anemia, which presents differently than IDA or thalassemia

Clinical Implications and Recommendations

The proper diagnosis and management of anemia during pregnancy are critical for maternal and fetal health. Given the complexities associated with differentiating between iron deficiency anemia (IDA) and thalassemia trait, especially in the context of pregnancy, the use of diagnostic tools such as the Mentzer Index and alternative indices is paramount.

1. Importance of Accurate Diagnosis

Accurate differentiation between types of anemia is essential for appropriate treatment and management. Misdiagnosis can lead to inappropriate interventions, such as unnecessary iron supplementation in patients with thalassemia trait, which can result in iron overload and related complications. Therefore, healthcare providers should employ a combination of diagnostic tools, including the Mentzer Index, serum ferritin levels, soluble transferrin receptor levels, and complete blood count parameters, to establish a definitive diagnosis. Clinicians should also consider clinical history, dietary habits, and risk factors when interpreting results to avoid misdiagnosis.

2. Holistic Patient Assessment

Given the physiological changes during pregnancy, a holistic assessment of the patient is necessary. This includes thorough history-taking to evaluate dietary intake, previous anemia episodes, and family history of hematological disorders. Providers should also assess the presence of any accompanying symptoms, such as fatigue, pallor, or shortness of breath, and conduct a physical examination. A comprehensive approach ensures that any underlying conditions, including other nutritional deficiencies or chronic diseases, are identified and addressed, thereby facilitating more effective management of anemia.

3. Education and Counseling

Patient education and counseling play a critical role in the management of anemia during pregnancy. Healthcare providers should educate pregnant women about the importance of maintaining adequate iron and nutrient intake, particularly from sources rich in iron, vitamin B12, and folate. Discussions about dietary adjustments, the potential need for supplements, and the importance of regular monitoring can empower patients to take an active role in their health. Providers should also discuss potential symptoms of anemia and advise when to seek medical attention, fostering a proactive approach to care.

4. Regular Monitoring and Follow-Up

Given the dynamic nature of pregnancy, regular monitoring of hemoglobin levels and other relevant parameters is essential for timely detection and management of anemia. Routine screening for anemia should be part of standard prenatal care, with follow-up testing conducted as necessary based on initial findings and clinical judgment. This allows for early intervention and adjustment of treatment plans, particularly in cases where anemia is identified or worsens during the course of pregnancy.

5. Multidisciplinary Collaboration

Anemia management in pregnancy often requires a multidisciplinary approach, involving obstetricians, hematologists, dietitians, and primary care providers. Collaboration among these professionals can ensure comprehensive care, addressing not only the anemia itself but also associated health issues. For instance, referral to a dietitian can provide patients with personalized nutritional guidance, while hematologists can offer expertise in cases of suspected thalassemia or other hematological disorders. This team-based approach can enhance patient outcomes and provide a supportive network for expectant mothers.

Conclusion

Anemia during pregnancy is a significant public health concern that can adversely affect maternal and fetal outcomes. The differentiation between iron deficiency anemia (IDA) and thalassemia trait is crucial for effective management, and the Mentzer Index serves as a valuable tool in this diagnostic process. By employing this index alongside alternative diagnostic methods—such as soluble transferrin receptor levels, ferritin measurements, and red cell distribution width—healthcare providers can obtain a comprehensive understanding of a patient's hematological status. Accurate diagnosis is essential for preventing inappropriate treatment, which can lead to complications like iron overload in patients with thalassemia. Moreover, a holistic patient assessment that incorporates dietary history, risk factors, and accompanying symptoms ensures that any underlying issues contributing to anemia are addressed. Education and counseling empower patients, promoting awareness of nutritional needs and encouraging proactive health management.

References

1. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, Ota E, Gilmour S, Shibuya K. Maternal anemia and risk of adverse birth and health outcomes in low-and middle-income countries: systematic review and meta-analysis. The American journal of clinical nutrition. 2016; 103(2):495-504.
2. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8.
3. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.
4. Petrakos G, Andriopoulos P, Tsironi M. Pregnancy in women with thalassemia: challenges and solutions. International journal of women's health. 2016:441-451.
5. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021 Apr;9(4):145-8.
6. Agreen FC, Obeagu EI. Anaemia among pregnant women: A review of African pregnant teenagers. Journal of Public Health and Nutrition. 2023;6(1):138.
7. Arora S, Rana D, Kolte S, Dawson L, Dhawan I. Validation of new indices for differentiation between iron deficiency anemia and beta thalessemia trait, a study in pregnant females. International Journal of Scientific Reports. 2018; 4(2):26.
8. Tabassum S, Khakwani M, Fayyaz A, Taj N. Role of Mentzer index for differentiating iron deficiency anemia and beta thalassemia trait in pregnant women. Pakistan Journal of Medical Sciences. 2022;38(4Part-II):878.
9. Matos JF, Dusse LM, Stubbert RV, Ferreira MR, Coura-Vital W, Fernandes AP, de Faria JR, Borges KB, Carvalho MD. Comparison of discriminative indices for iron deficiency anemia and β thalassemia trait in a Brazilian population. Hematology. 2013 May 1;18(3):169-74.
10. Iolascon A, Andolfo I, Russo R, Sanchez M, Busti F, Swinkels D, Aguilar Martinez P, Bou-Fakhredin R, Muckenthaler MU, Unal S, Porto G. Recommendations for diagnosis, treatment, and prevention of iron deficiency

and iron deficiency anemia. Hemasphere. 2024; 8(7):e108.
11. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of protein C, protein S and fibrinogen of pregnant women with malaria in Owerri metropolis. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Apr 19;2(2):1-9.
12. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
13. Sahli CA, Bibi A, Ouali F, Fredj SH, Dakhlaoui B, Othmani R, Laouini N, Jouini L, Ouenniche F, Siala H, Touhami I. Red cell indices: differentiation between β-thalassemia trait and iron deficiency anemia and application to sickle-cell disease and sickle-cell thalassemia. Clinical Chemistry and Laboratory Medicine (CCLM). 2013; 51(11):2115-24.
14. Hoffmann JJ, Nabbe KC, van den Broek NM. Effect of age and gender on reference intervals of red blood cell distribution width (RDW) and mean red cell volume (MCV). Clinical Chemistry and Laboratory Medicine (CCLM). 2015; 53(12):2015-9.
15. Miftahussurur M, Husada D, Ningtyas WS. ASSOCIATION ASSOCIATION OF SHINE AND LAL INDEX β-THALASSEMIA TRAIT SCREENING RESULTS WITH ANAEMIA AND LOW BIRTH WEIGH. INTERNATIONAL JOURNAL OF NURSING AND MIDWIFERY SCIENCE (IJNMS). 2023; 7(3):290-296.
16. Shahid H, Saleem M, Naseer N, Tabussam S, Aziz A, Ullah S. Evaluation of Srivastava index to distinguishing Beta-Thalassemia Trait from Iron Deficiency. Pakistan Journal of Medical & Health Sciences. 2022;16(05):1225-.
17. Vehapoglu A, Ozgurhan G, Demir AD, Uzuner S, Nursoy MA, Turkmen S, Kacan A. Hematological indices for differential diagnosis of Beta thalassemia trait and iron deficiency anemia. Anemia. 2014; 2014(1):576738.
18. Urrechaga E. Discriminant value of% microcytic/% hypochromic ratio in the differential diagnosis of microcytic anemia. Clinical chemistry and laboratory medicine. 2008;46(12):1752-1758.
19. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18

Access this Article in Online

Website: www.ijcrims.com

Subject: Health Sciences.

Quick Response Code

DOI: 10.22192/ijcrms.2024.10.10.05

How to cite this article:
Emmanuel Ifeanyi Obeagu and Getrude Uzoma Obeagu. (2024). Mentzer Index and Pregnancy: Utility in Differentiating Iron Deficiency Anemia and Thalassemia. Int. J. Curr. Res. Med. Sci. 10(10): 32-41. DOI: http://dx.doi.org/10.22192/ijcrms.2024.10.10.005